North America Biotechnology And Pharmaceutical Services Outsourcing Market Size | Companies
The North America biotechnology and pharmaceutical services outsourcing market size was exhibited at USD 12.85 billion in 2023 and is projected to hit around USD 21.21 billion by 2033, growing at a CAGR of 5.14% during the forecast period 2024 to 2033.
Changes in regulatory landscape, the strong presence of pharmaceutical & biotechnology companies, growing focus on core business activities by biotechnology and pharmaceutical firms and rise in economic & competitive pressures are some of the factors driving market growth. Furthermore, rising demand for skilled regulatory affairs experts and consultants with expertise in data management for pharmaceutical and biotech firms is anticipated to propel overall market growth.
Rising drug development costs, lessening internal R&D development capabilities, increasing regulatory frameworks, and low-cost service deployment to contract research organizations (CROs) and contract manufacturing organizations (CMOs) are some of the major factors driving market growth.
| Report Coverage | Details |
| Market Size in 2024 | USD 13.51 Billion |
| Market Size by 2033 | USD 21.21 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 5.14% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Service, End use, Country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Country scope | U.S.; Canada; Mexico; Puerto Rico |
| Key Companies Profiled | The Quantic Group; IQVIA; Parexel International Corporation; Lachman Consultant Services, Inc.; GMP Pharmaceuticals Pty Ltd.; LabCorp; Charles River Laboratories; ICON plc; Syneos Health; Lonza; Catalent Inc.; Samsung Biologics |
Growing investments in R&D activities in the biopharmaceutical industry are expected to positively impact on the overall outsourcing market. As pharmaceutical firms are proactively involved in the discovery and development of novel drug formulations, there is a growing need for several advanced services to ensure the safety & efficacy of these products. R&D activities drive the development of new pharmaceuticals, biologics, and vaccines, necessitating comprehensive sterility testing methodologies to comply with regulatory requirements. Pharmaceutical and biotechnology companies are now focusing on their core competencies and outsourcing noncore functions to increase their productivity & operational efficiency. These companies frequently outsource R&D activities to CROs to reduce costs & increase focus on core functions. Small and medium-scale companies, which do not have in-house capabilities, have to outsource their regulatory affairs to enter into new markets. Thus, factors above are driving overall market growth in North America.
Biotechnology and pharmaceutical companies have to deal with continuous changes in regulatory requirements. Noncompliance with the changing regulatory requirement can result in penalties and delays, which may lead to loss of revenue. According to a survey sponsored by Genpact, 72.0% of executives from the life sciences industry consider regulatory compliance as one of the top three challenges faced by life sciences companies. Regulatory departments often face the burden of handling multiple tasks simultaneously and have to ensure compliance with stringent regulatory standards at all times. An increase in efforts by companies to expand their geographic reach and gain rapid approvals is expected to further contribute to the adoption of outsourcing models for regulatory services.
High clinical development failure rates further enhanced the need for outsourcing in the biotechnology and pharmaceutical sectors. Approximately 90% of drug candidates fail to progress from clinical trials to market approval, representing a significant risk and financial loss for companies. Outsourcing mitigates this risk by leveraging the expertise and infrastructure of CROs and other service providers. These external partners possess specialized knowledge in clinical trial design, regulatory compliance, and patient recruitment, increasing the likelihood of successful outcomes and reducing the overall risk associated with drug development.
In pharmaceuticals and biopharmaceutical companies, innovations and speed-to-clinic factors are significantly important. In addition, specialty pharmaceuticals and biopharmaceutical players rely on one-stop-shop CDMOs to deliver these requirements in the industry. Many CDMOs promote themselves as one-stop-shop CDMOs. In this service model, a CDMO handles everything from API to dosage form and early development to commercialization. However, to provide these services, a CDMO must have a range of technologies and handling capabilities to address problem statements. There is a wide range of product design capabilities among CDMO players that can be critical in scaling a product concept and bringing it to the market.
The one-stop-shop service model is not completely influenced by sponsors; it is a response by CMOs seeking M&A at lower costs within the fragmented contract pharma manufacturing space. CRO and CMO companies provide one-stop services, which is their primary avenue for growth. The outsourcing industry has benefitted significantly from sponsor consolidation, primarily from acquiring facilities & personnel and M&As to expand their service portfolios & geographic presence by acquiring niche providers. For instance, in March 2024, Pace Life Sciences, LLC acquired New Jersey Laboratory from Curia to support its drug development partners with commercialization activities.
The consulting services segment held the largest revenue share, over 26.0% of the overall revenue size, in 2023 and is predicted to maintain its position over the analysis timeframe. The high segment growth is primarily attributed to increased demand for CRO consultants in the industry. Furthermore, the increasing focus on personalized medicine and the incorporation of digital health solutions is leading to a growing demand for consulting expertise. The sector is also undergoing consolidation, with larger consulting firms acquiring niche players to expand their service range and gain a competitive edge.
The regulatory affairs segment is expected to be the fastest-growing segment over the forecast period due to stringent regulatory requirements in developed countries such as the U.S. and changing regulatory reforms in emerging countries such as Mexico and Puerto Rico. In addition, technological advancements in drug manufacturing and the growth of the biotechnology and pharmaceutical sectors across the region are key factors propelling segment growth. Moreover, an increasing prevalence of chronic diseases, such as cardiovascular diseases and cancer, is anticipated to boost market growth over the forecast period.
The pharmaceutical companies segment dominated the market share 60.0% in 2023 and is anticipated to witness a CAGR of 4.86 % over the forecast period. Growing R&D spending by pharmaceutical companies for development of potential novel products and a rise in investments by CROs for development of core capabilities are major factors driving market demand in the upcoming years. Furthermore, an increasing number of small- & medium-sized companies are outsourcing their production work to CDMOs and CMOs. Small- and medium-sized pharmaceutical companies have limited resources & capabilities in formulation development, product design & development, and regulatory services, thereby boosting the pharmaceutical and biotechnology services outsourcing market. Cost pressures and the need for operational efficiency are leading pharmaceutical companies to increasingly outsource R&D, clinical trials, and manufacturing processes to specialized service providers.
On the other hand, the biotechnology companies segment is expected to witness the fastest revenue growth over the forecast period. This growth can be attributed to a lack of capacity & capability to perform regulatory affairs functions and the presence of stringent regulatory requirements in developed countries. Furthermore, lowering profit margins, coupled with rising competition in the market, are contributing to market growth. In addition, easy access to industry experts is another factor accelerating the demand for outsourcing services.
U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Trends
The biotechnology and pharmaceutical services outsourcing market in the U.S. dominated the regional market and accounted for the largest revenue share of over 87.37% in 2023. Several pharmaceutical & biotechnology companies are increasingly outsourcing their development & manufacturing activities to CROs, CMOs, & CDMOs to minimize product lifecycle costs, accelerate time-to-market, and access specialized expertise. In addition, several pharmaceutical & biotechnology companies outsource part of their regulatory functions to meet the evolving regulation requirements, risk mitigations, and quality assurance, contributing to market growth. High R&D spending on clinical trials is another major factor expected to fuel market growth. For instance, in October 2021, the U.S. FDA approved 11 new clinical trial research, resulting in over USD 25 million in funding over the next four years. These grants aim to support the development of new medical products specifically for treating rare diseases.
The biotechnology and pharmaceutical services outsourcing market in Canada held a considerable market share in 2023. This growth is attributed to the rising technological innovations, growing demand for personalized medicine, and increasing number of clinical trials in Canada, which are some of the major factors expected to improve the demand for biotechnology & pharmaceutical services outsourcing. For instance, in February 2023, Roche announced the extended collaboration with Janssen Biotech Inc. to create companion diagnostics for targeted therapies, strengthening the company’s research & innovation activities. The agreement would provide opportunities for both companies to collaborate in precision medicine with multiple companion diagnostics technologies, such as digital pathology, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), PCR, and immunoassays.
Moreover, according to the Government of Canada, Canada has one of the highest numbers of biotechnology companies worldwide focused on human health, giving the country a strong record of achievement in biopharmaceuticals. In addition, the notable trend toward outsourcing drug development and production to CROs, CMOs, and CDMOs and leveraging their expertise and specialized services is fueling market growth in Canada.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the North America biotechnology and pharmaceutical services outsourcing market
Service
End Use
Country
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers